Goyal, Mayank http://orcid.org/0000-0001-9060-2109
McTaggart, Ryan
Ospel, Johanna M.
van der Lugt, Aad
Tymianski, Michael
Wiest, Roland
Lundberg, Johan
von Kummer, RĂ¼diger
Hill, Michael D.
Luijten, Sven
Roozenbeek, Bob
Saver, Jeffrey L.
McDonough, Rosalie V.
Article History
Received: 8 February 2022
Accepted: 21 June 2022
First Online: 20 July 2022
Declarations
:
: Drs. McDonough, McTaggart, Roozenbeek, Luijten, Wiest, and Lundberg report no conflicts. Dr. Ospel reports being a consultant for NICOLab. Dr. Saver reports being an employee of the University of California; serving as an unpaid site investigator in multicenter trials run by Medtronic and Stryker for which the University of California Regents received payments on the basis of clinical trial contracts for the number of subjects enrolled; and receiving funding for services as a scientific consultant regarding trial design and conduct to Medtronic, Stryker, Cerenovus and Rapid Medical. The UC Regents have patent rights in endovascular retrievers. Dr. Hill reports unrestricted grant funding for the ESCAPE trial to University of Calgary from Covidien/Medtronic, and active/in-kind support consortium of public/charitable sources (Heart and Stroke Foundation, Alberta Innovates Health Solutions, Alberta Health Services) and the University of Calgary (Hotchkiss Brain Institute, Departments of Clinical Neurosciences and Radiology, and Calgary Stroke Program); grant funding from Boehringer Ingelheim, NoNo, Inc, and Stryker. Personal fees from Merck, nonfinancial support from Hoffmann-La Roche Canada. In addition, Dr Hill has a submitted patent for triaging systems in ischemic stroke and owns stock in Calgary Scientific, a company that focuses on medical imaging software. Dr. Goyal reports receiving an unrestricted institutional grant from Medtronic; he received a grant from Stryker and consulting fees from Stryker, MicroVention, Mentice; he holds patent rights in systems and methods for acute stroke diagnosis with GE Healthcare. Dr. Van der Lugt reports unrestricted grants from Stryker, Penumbra, Medtronic, Cerenovus, Thrombolytic Science, LLC, Dutch Heart Foundation, Brain Foundation Netherlands, The Netherlands Organization for Health Research and Development, and Health Holland Top Sector Life Sciences & Health for research, paid to institution. Dr. Tymianski is the CEO of NoNO Inc., a biotechnology company that has sponsored the ENACT, ESCAPE-NA1, and ESCAPE-NEXT trials. Dr. von Kummer is the Editor-in-Chief of <i>Neuroradiology.</i>
: Not applicable.
: Not applicable.
Free to read: This content has been made available to all.